CHADI CALARGE to Bone Density
This is a "connection" page, showing publications CHADI CALARGE has written about Bone Density.
Connection Strength
2.766
-
Examining Whether Genetic Variants Moderate the Skeletal Effects of Selective Serotonin Reuptake Inhibitors in Older Adolescents and Young Adults. J Child Adolesc Psychopharmacol. 2023 09; 33(7):260-268.
Score: 0.707
-
Bone Mass in Boys with Autism Spectrum Disorder. J Autism Dev Disord. 2017 06; 47(6):1749-1755.
Score: 0.461
-
Longitudinal examination of the skeletal effects of selective serotonin reuptake inhibitors and risperidone in boys. J Clin Psychiatry. 2015 May; 76(5):607-13.
Score: 0.399
-
Major depressive disorder and bone mass in adolescents and young adults. J Bone Miner Res. 2014 Oct; 29(10):2230-7.
Score: 0.383
-
Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mineral density in risperidone-treated boys: a reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics. J Clin Psychiatry. 2011 Dec; 72(12):1685-90.
Score: 0.315
-
A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry. 2010 Mar; 71(3):338-47.
Score: 0.279
-
Calcium and Vitamin D Supplementation in Boys with Risperidone-Induced Hyperprolactinemia: A Randomized, Placebo-Controlled Pilot Study. J Child Adolesc Psychopharmacol. 2018 03; 28(2):145-150.
Score: 0.119
-
Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth. J Child Adolesc Psychopharmacol. 2016 06; 26(5):471-7.
Score: 0.105